Pharmaceutical Salt Formation for Rapid Herpes Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical preparations for treating herpes diseases caused by herpes simplex viruses exhibit delayed release of the active compound N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide, which is therapeutically undesirable and lacks storage stability.
Innovation Solution
Incorporating a specific quantitative proportion of acid, such as hydrochloric acid, acetic acid, sulfuric acid, lactic acid, or benzoic acid, during the production of pharmaceutical preparations through combined wet granulation with the active compound, forming a salt, which enhances both the speed of release and storage stability without the need for gas generating substances.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional pharmaceutical excipients are used without acid components, then the preparation can be manufactured with simple composition, but the active compound exhibits delayed release and poor storage stability
Solution Approach 1:
The invention changes the chemical environment parameter by introducing acid components (citric acid, sorbic acid, propionic acid, benzoic acid, or stearic acid) into the tablet formulation. This parameter change prevents clumping and gel formation of the active compound, thereby achieving both fast release (≥80% within 30 minutes) and improved storage stability without complicating the manufacturing process
Solution Approach 2:
Acid components serve as intermediary substances that mediate between the active compound and the tablet matrix. These acids prevent direct interaction between the active compound and other excipients that would cause delayed release, while also providing stabilizing effects during storage
2Speed
If conventional excipients are used without acid, then the formulation remains simple, but release speed is delayed which is therapeutically undesirable
Solution Approach 1:
By changing the pH parameter through acid addition, the invention transforms the release characteristics from delayed to fast release. The acid components create a favorable chemical environment that prevents gel formation and ensures rapid dissolution of the active compound in gastrointestinal fluids
Solution Approach 2:
The acid components are pre-incorporated into the tablet during manufacturing to prevent clumping and gel formation before the tablet reaches the patient. This preliminary action ensures that the active compound is already in a state ready for fast release upon administration
3Speed
If gas generating substances are added to accelerate release, then release speed improves, but the formulation complexity and potential side effects increase
Solution Approach 1:
The invention extracts and eliminates gas generating substances (such as sodium carbonate) from the formulation while achieving the desired fast release effect through acid components alone. This removes potential harmful factors while maintaining therapeutic efficacy
Solution Approach 2:
The invention uses simple, inexpensive acid components that perform their function rapidly and then are safely metabolized or excreted, replacing complex gas-generating systems with simpler, safer alternatives
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves rapid release of at least 80% of the active compound within 30 minutes and maintains stability for up to six years, ensuring effective treatment and prophylaxis of herpes viruses.
Implementation Method 1
the acetamide and the acid form a salt
Data Source
AI summary
The invention relates to a pharmaceutical preparation for oral administration comprising N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide or its hydrates and/or solvates, as well as an acid, a method for its production as well as the use of this preparation for the treatment and/or prophylaxis of diseases which are caused by herpes viruses, in particular diseases which are caused by herpes simplex viruses.